Portola jumps on Priority Review for betrixaban

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) gained $6.33 (34%) to $25.06 after it said

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE